About

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial

EULAR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.

Publication thumbnail: One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice:  A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib

AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab

Steering Committee